Intellia Therapeutics, Inc. (LON:0JBU)

Intellia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-519.02	-481.19	-474.19	-267.89	-134.23
Depreciation & Amortization	10.29	8.98	7.57	6.89	6.31
Loss (Gain) From Sale of Assets	-0.08	0.07	-0.16	-	0.04
Asset Writedown & Restructuring Costs	-	-	55.99	-	-
Loss (Gain) From Sale of Investments	-6.22	-19.27	15.41	10.54	0.54
Loss (Gain) on Equity Investments	-	15.63	11.08	1.33	-
Stock-Based Compensation	154.27	134.05	91.4	47.01	19.9
Other Operating Activities	-	0.1	13.49	-	-
Change in Accounts Receivable	27.94	-32.69	-1.74	0.1	2.49
Change in Accounts Payable	6.8	2.52	-4.58	0.53	5.06
Change in Unearned Revenue	-22.08	-2.78	-63.46	-31.36	45.12
Change in Other Net Operating Assets	-0.79	-19.51	15.91	7.82	4.86
Operating Cash Flow	-348.88	-394.09	-333.29	-225.03	-49.91
Capital Expenditures	-5.78	-13.99	-13.56	-12.76	-3.59
Sale of Property, Plant & Equipment	-	-	0.15	-	-
Sale (Purchase) of Intangibles	-	-	-44.83	-	-
Investment in Securities	131.35	-17.36	218.55	-538.02	-210.9
Investing Cash Flow	125.57	-31.35	160.31	-550.78	-214.49
Issuance of Common Stock	185.75	130.32	582.96	736.69	371.78
Financing Cash Flow	185.75	130.32	582.96	736.69	371.78
Net Cash Flow	-37.57	-295.11	409.98	-39.12	107.38
Free Cash Flow	-354.66	-408.07	-346.85	-237.79	-53.5
Free Cash Flow Margin	-612.78%	-1124.94%	-665.46%	-719.41%	-92.25%
Free Cash Flow Per Share	-3.59	-4.60	-4.51	-3.35	-0.96
Levered Free Cash Flow	-133.38	-268.21	-256.18	-69.57	-43.46
Unlevered Free Cash Flow	-133.38	-268.21	-256.18	-69.57	-43.46
Change in Net Working Capital	-41.76	75.19	10.41	-56.69	-19.28

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.